[1] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016,66(2):115-132.
[2] Hospital Authority of National Health and Family Planning Commission of the People′s Republic of China, Chinese Society of Oncology. Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer (2017 edition). Chin J Surg(中华外科杂志), 2018, 56(4):241-258.
[3] Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer working group.Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version) . Chin J Cancer(癌症),2019, 31(1):117-134.
[4] National Comprehensive Cancer Network. Rectal Cancer (version 3.2018) . http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.
[5] National Comprehensive Cancer Network. Colon Cancer (version 4.2018). http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
[6] SALTZ L B, CLARKE S, DIAZ-RUBIO E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:a randomized phase Ⅲ study. Clin Oncol, 2008, 26:2013-2019.
[7] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Antiemensis,Version 3.2018. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.
[8] MAINDRAULTGOEBEL F, DE G A, LOUVET C, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).. Annals Oncol, 2000, 11(11):1477-1483.
[9] CHEESEMAN S L, JOEL S P, CHESTER J D, et al. A modified de Gramont regimen offluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br.. Cancer, 2002, 87(4):393-399.
[10] CUNNINGHAM D, LANG I, MARCUELLO E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX):an open-label, randomised phase 3 trial.. Lancet Oncol, 2013, 14(11):1077-1085.
[11] ANDRE T, LOUVET C, MAINDRAULT-GOEBEL F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. Cancer,1999, 35(9):1343-1347.
[12] FUCHS C S, MARSHALL J, MITCHELL E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer:results from the BICC-C study. Clin Oncol, 2007, 25(30):4779-4786.
[13] FALCONE A, RICCI S, BRUNETTI I, et al. Phase Ⅲ trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan(FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan(FOLFIRI) as first-line treatment for metastatic colorectal cancer:The Gruppo Oncologico Nord Ovest. Clin Oncol, 2007, 25(13):1670-1676.
[14] EMMANOUILIDES C, SFAKIOTAKI G, ANDROULAKIS N, et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer:a multicenter phase Ⅱ study. BMC Cancer, 2007, 7(1):91-97.
[15] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3):a randomised, open-label, phase 3 trial. The Lancet Oncol, 2014, 15(10):1065-1075.
[16] CREMOLINI C, LOUPAKIS F, ANTONIOTTI C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer:update of overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol,2015, 16(13):1306-1315.
[17] VENOOK A P, NIEDZWIECKI D, LENZ H J, et al. CALGB/SWOG 80405:Phase Ⅲ trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab or cetuximab for patients with KRAS wild-type untreated metastatic adenocarcinoma of the colon or rectum. Annals Oncol, 2014,25(s2):112-113.
[18] VAN CUTSEM E, TEJPAR S, VANBECKEVOORT D, et al. Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions:The Randomized EVEREST Study. Clin Oncol, 2012, 30(23):2861-2868.
[19] MARTíN-MARTORELL P, ROSELLS, RODRíGUEZ-BRAUN E, et al. Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy:results of a phase Ⅱ single institution trial. Cancer,2008, 99(3):455-458.
[20] Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT):an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 2013, 381(9863):303-312.
[21] BEKAII-SAAB T S, OU F S, ANDERSON D M, et al. Regorafenib dose optimization study (ReDOS): randomized phase Ⅱ trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)—an ACCRU network study. J Clin Oncol 2018, 36(suppl 4S):611.
[22] LI J, QIN S, XU R H, et al. Effect of Fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer:the FRESCO randomized clinical trial. JAMA, 2018, 319(24):2486-2496.
[23] LE D T, URAM J N, WANG H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med, 2015, 372(20):2509-2520.
[24] OVERMAN M J, KOPETZ S, LONARDI S, et al. Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the check Mate-142 study. Ann Oncol, 2016, 27(suppl 6):479.